Resource impact statement
No significant resource impact is anticipated
NICE has recommended secukinumab for treating active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs) in adults only if tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough.
People with radiographic axial spondyloarthritis (also known as ankylosing spondylitis) are already eligible for secukinumab under NICE's technology appraisal guidance on secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or £9,000 per 100,000 population).
This is because the technology is a further treatment option, the overall cost of treatment will be similar and we do not think practice will change substantially as a result of this guidance.
Secukinumab and some of the other treatment options have discounts that are commercial in confidence.
A resource impact template is provided for completion at a local level. This is because there are numerous treatment options that are recommended by NICE for treating axial spondyloarthritis.
This technology is commissioned by integrated care systems / clinical commissioning groups. Providers are NHS hospital trusts.
This page was last updated: